Most oncology treatments that received the FDA’s accelerated approval pathway in the past 25 years have demonstrated a clinical benefit, according to a review by agency officials published in the journal JAMA Oncology.
Source: Drug Industry Daily
Most oncology treatments that received the FDA’s accelerated approval pathway in the past 25 years have demonstrated a clinical benefit, according to a review by agency officials published in the journal JAMA Oncology.
Source: Drug Industry Daily